This SDS packet was issued with item: 078447060

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078447045 078447086 078447102 078447128 078447144 078447169 078447185 078447201



Revision date: 06-Oct-2013

Version: 2.0

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Carprofen caplets

Trade Name: Chemical Family:

Intended Use: Restrictions on Use: RIMADYL(R) Caplets Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Veterinary product used as non-steroidal, anti-inflammatory drug (nsaid) Not for human use

Details of the Supplier of the Safety Data Sheet

Zoetis Inc. 100 Campus Drive, P.O. Box 651 Florham Park, New Jersey 07932 (USA) Rocky Mountain Poison Control Center Phone: 1-866-531-8896 Product Support/Technical Services Phone: 1-800-366-5288

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: VMIPSrecords@zoetis.com Zoetis Belgium S.A. Mercuriusstraat 20 1930 Zaventem Belgium

Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Appearance:

Yellow orange, capsule shaped, biconvex caplets imprinted on front with "RIMADYL" and scored on back and imprinted with "25, 75 or 100"

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 2 Specific target organ systemic toxicity (repeated exposure): Category 2


EU Classification:

EU Indication of danger: Not classified

Label Elements

Signal Word: Hazard Statements:	Warning H361d - Suspected of damaging the unborn child H373 - May cause damage to organs through prolonged or repeated exposure
Precautionary Statements:	 P201 - Obtain special instructions before use P202 - Do not handle until all safety precautions have been read and understood P260 - Do not breathe dust/fume/gas/mist/vapors/spray P280 - Wear protective gloves/protective clothing/eye protection/face protection P308 + P313 - IF exposed or concerned: Get medical attention/advice P405 - Store locked up P501 - Dispose of contents/container in accordance with all local and national regulations

Material Name: Carprofen caplets Revision date: 06-Oct-2013



3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Starch, pregelatinized	9005-25-8	232-679-6	Not Listed	Not Listed	*
Carprofen	53716-49-7	258-712-4	Repr.Cat.3;R63 T;R25 Xn;R48/22	Acute Tox 3 (H301) Repro 2 (H361d) STOT Re 2 (H373)	2
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	Not Listed	*
Magnesium Stearate	557-04-0	209-150-3	Not Listed	Not Listed	*
Colloidal silicon dioxide	7631-86-9	231-545-4	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Lactose hydrous	64044-51-5	Not Listed	Not Listed	Not Listed	*
Sodium starch glycolate	9063-38-1	Not Listed	Not Listed	Not Listed	*
Yellow lake blend	MIXTURE	Not Listed	Not Listed	Not Listed	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

	4. FIRST AID MEASURES
Eye Contact:	Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.
Skin Contact:	Wash skin with soap and water. If irritation occurs or persists, get medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
ost Important Symptoms and Effe Symptoms and Effects of Exposure: Medical Conditions Aggravated by Exposure:	ects, Both Acute and Delayed For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information. None known
dication of the Immediate Medica Notes to Physician:	al Attention and Special Treatment Needed None
	5. FIRE-FIGHTING MEASURES
xtinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
pecial Hazards Arising from the S Hazardous Combustion Products:	Substance or Mixture May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.
Fire / Explosion Hazards:	Not applicable
•	
dvice for Fire-Fighters	, wear appropriate protective equipment, including self-contained breathing apparatus.
dvice for Fire-Fighters During all fire fighting activities	e, wear appropriate protective equipment, including self-contained breathing apparatus.
dvice for Fire-Fighters During all fire fighting activities 6 ersonal Precautions, Protective E Personnel involved in clean-up	
dvice for Fire-Fighters During all fire fighting activities 6 ersonal Precautions, Protective E Personnel involved in clean-up nvironmental Precautions	ACCIDENTAL RELEASE MEASURES
dvice for Fire-Fighters During all fire fighting activities 6 ersonal Precautions, Protective E Personnel involved in clean-up nvironmental Precautions	ACCIDENTAL RELEASE MEASURES Equipment and Emergency Procedures o should wear appropriate personal protective equipment (see Section 8). Minimize exposure. y labeled, sealed container for disposal. Care should be taken to avoid environmental release.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Page 4 of 10 Version: 2.0

7. HANDLING AND STORAGE

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Storage Temperature: Specific end use(s): Store as directed by product packaging. 15 - 30 °C No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Starch, pregelatinized	
ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELS - TWAs:	15 mg/m³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL -TWAs	3 mg/m ³
Carprofen	
Zoetis OEL TWA 8-hr	1000 µg/m³
T 1. (
Talc (non-asbestiform)	0
ACGIH Threshold Limit Value (TWA)	2 mg/m^3
Australia TWA	2.5 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Belgium OEL - TWA	2 mg/m ³
Bulgaria OEL - TWA	1.0 fiber/cm3 6.0 mg/m ³
	3.0 mg/m^3
Czech Republic OEL - TWA	2.0 mg/m ³
Czech Republic OEL - TWA	10 mg/m ³
Denmark OEL - TWA	0.3 fiber/cm3
Finland OEL - TWA	0.5 fiber/cm3
Greece OEL - TWA	10 mg/m^3
	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	0.8 mg/m ³

	OLS / PERSONAL PROTECTION
Lithuania OEL - TWA	2 mg/m ³
	2 mg/m ³
Netherlands OEL - TWA	0.25 mg/m^3
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
Poland OEL - TWA	4.0 mg/m ³
	1.0 mg/m^3
Portugal OEL - TWA	2 mg/m^3
Slovakia OEL - TWA	2 mg/m ³
	10 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Spain OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	2 mg/m ³
	1 mg/m ³
Switzerland OEL -TWAs	2 mg/m ³
Magnesium Stearate	
ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAS	5 mg/m ³
	3 mg/m
Colloidal silicon dioxide	
Australia TWA	2 mg/m ³
Austria OEL - MAKs	4 mg/m ³
	0.3 mg/m ³
Czech Republic OEL - TWA	0.1 mg/m ³
	4.0 mg/m ³
Estonia OEL - TWA	2 mg/m ³
Finland OEL - TWA	5 mg/m ³
Germany - TRGS 900 - TWAs	4 mg/m ³
Germany (DFG) - MAK	4 mg/m ³
Ireland OEL - TWAs	6 mg/m ³
	2.4 mg/m ³
Latvia OEL - TWA	1 mg/m ³
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
Slovakia OEL - TWA	Listed
Siovakia OEL - TWA Switzerland OEL -TWAs	4.0 mg/m ³ 4 mg/m ³
Switzenand OEL - I WAS	4 mg/m ² 0.3 mg/m ³
The exposure limit(s) listed for solid components are only rel	•

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Exposure Controls Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Yellow orange No data available.

Mixture

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory protection:

Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

Color:

Odor Threshold: Molecular Weight:

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Caplets
Odor:	Odorless
Molecular Formula:	Mixture
	N 1 1 7 11 11
Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, E	ndpoint, Value)
No data available	
Decomposition Temperature (°C):	No data available.
Evaporation Rate (Gram/s):	No data available
Vapor Pressure (kPa):	No data available
Vapor Density (g/ml):	No data available
Relative Density:	No data available
Viscosity:	No data available
Flammablity:	

Autoignition Temperature (Solid) (°C): Flammability (Solids): Flash Point (Liquid) (°C): Upper Explosive Limits (Liquid) (% by Vol.): Lower Explosive Limits (Liquid) (% by Vol.): Polymerization:

No data available Will not occur

10. STABILITY AND REACTIVITY

No data available

Reactivity: Chemical Stability: Possibility of Hazardous Reactions Oxidizing Properties: Conditions to Avoid: Incompatible Materials: Hazardous Decomposition Products:

Stable None None known As a precautionary measure, keep away from strong oxidizers See Section 5 - under Hazardous combustion products.

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

11. TOXICOLOGICAL INFORMATION

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Carprofen

Mouse Oral LD50 282 mg/kg Rat Oral LD50 149mg/kg Rat (M/F) SC LD50 230/190mg/kg Rat (M/F) IP LD50 140/110 mg/kg Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Carprofen

Eye Irritation Rabbit Non-irritating Skin Irritation Rabbit Non-irritating Skin Sensitization - GPMT Guinea Pig Negative Antigenicity- Delayed skin reaction Guinea Pig No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Carprofen

13 Week(s) Rat Oral5 mg/kg/day NOAEL Gastrointestinal System 13 Week(s) Dog Oral 5 mg/kg/day NOAEL None identified

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Carprofen

Reproductive & Fertility Rat 20 mg/kg/day Fetotoxicity, Maternal toxicity NOAEL Embryo / Fetal Development Rat 20 mg/kg/day NOAEL Not Teratogenic Prenatal & Postnatal Development Mouse 40 mg/kg/day NOAEL Not Teratogenic Prenatal & Postnatal Development Rabbit Oral 6 mg/kg/day Embryotoxicity, Early embryonic development NOAEL

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Carprofen

Bacterial Mutagenicity (Ames)SalmonellaNegativeIn Vivo MicronucleusMouseNegative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Carprofen

2 Year(s) Rat Oral 10 mg/kg/day NOAEL Not carcinogenic, Gastrointestinal system 2 Year(s) Dog Oral 25 mg/kg/day NOAEL Not carcinogenic, No effects at maximum dose

Carcinogen Status:	None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below
Talc (non-asbestiform) IARC:	Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

properties have not been thoroughly investigated. Releases to the environment ded.
ble
ble
ble
ble

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications WHMIS hazard class: Class D, Division 2, Subdivision A



15. REGULATORY INFORMATION

Lactose hydrous	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Starch, pregelatinized	N 1 (1) (1)
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present Present
Australia (AICS): REACH - Annex IV - Exemptions from the	Present
obligations of Register:	Flesen
EU EINECS/ELINCS List	232-679-6
Sodium starch glycolate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS): EU EINECS/ELINCS List	Present
EU EINECS/ELINCS LIST	Not Listed
Carprofen	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 4
for Drugs and Poisons:	050 740 4
EU EINECS/ELINCS List	258-712-4
Talc (non-asbestiform)	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	238-877-9
Magnesium Stearate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3
Colloidal silicon dioxide	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-545-4
	-

15. REGULATORY INFORMATION

Yellow lake blend

CERCLA/SARA 313 Emission reporting California Proposition 65 EU EINECS/ELINCS List Not Listed Not Listed Not Listed

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed

Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

Data Sources:	The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.
Reasons for Revision:	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection.

Prepared by:

Toxicology and Hazard Communication Zoetis Global Risk Management

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet